Reach Neuro’s Avantis Platform Receives the US FDA’s Breakthrough Device Designation for Chronic Stroke
Shots:
- The US FDA has granted the Breakthrough Device designation to the Avantis platform for restoring movement. Avantis device delivers small electrical impulses to the spinal cord to restore shoulder, arm & hand movement in individuals with impairment due to chronic stroke
- Recently published findings showed 40% & 108% improvements in grip strength in the first 2 study participants, and ~124% improvement in joint strength, participants successfully performed functional tasks
- Improvements were retained ~1mos. after the study even without stimulation. The company develops implantable neuromodulation systems to help patients recover upper limb motor function after a chronic stroke & other neurological conditions
Ref: PRNewswire | Image: Reach Neuro
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
